JP2021512926A5 - - Google Patents

Info

Publication number
JP2021512926A5
JP2021512926A5 JP2020542907A JP2020542907A JP2021512926A5 JP 2021512926 A5 JP2021512926 A5 JP 2021512926A5 JP 2020542907 A JP2020542907 A JP 2020542907A JP 2020542907 A JP2020542907 A JP 2020542907A JP 2021512926 A5 JP2021512926 A5 JP 2021512926A5
Authority
JP
Japan
Prior art keywords
free acid
group
absence
reaction conditions
under suitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512926A (ja
JP7431163B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017448 external-priority patent/WO2019157426A1/en
Publication of JP2021512926A publication Critical patent/JP2021512926A/ja
Publication of JP2021512926A5 publication Critical patent/JP2021512926A5/ja
Application granted granted Critical
Publication of JP7431163B2 publication Critical patent/JP7431163B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542907A 2018-02-09 2019-02-11 4-クロロキヌレニンおよび中間体の合成 Active JP7431163B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628580P 2018-02-09 2018-02-09
US62/628,580 2018-02-09
PCT/US2019/017448 WO2019157426A1 (en) 2018-02-09 2019-02-11 Synthesis of 4-chlorokynurenines and intermediates

Publications (3)

Publication Number Publication Date
JP2021512926A JP2021512926A (ja) 2021-05-20
JP2021512926A5 true JP2021512926A5 (cg-RX-API-DMAC7.html) 2022-02-22
JP7431163B2 JP7431163B2 (ja) 2024-02-14

Family

ID=67548039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542907A Active JP7431163B2 (ja) 2018-02-09 2019-02-11 4-クロロキヌレニンおよび中間体の合成

Country Status (6)

Country Link
US (1) US11427530B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749638B1 (cg-RX-API-DMAC7.html)
JP (1) JP7431163B2 (cg-RX-API-DMAC7.html)
CN (2) CN112236412B (cg-RX-API-DMAC7.html)
CA (1) CA3127220C (cg-RX-API-DMAC7.html)
WO (1) WO2019157426A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112236412B (zh) * 2018-02-09 2024-01-30 维斯塔津治疗公司 4-氯代犬尿氨酸及中间体的合成
WO2022082100A1 (en) * 2020-10-16 2022-04-21 Vistagen Therapeutics, Inc. Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof
CA3241944A1 (en) * 2021-12-23 2023-06-29 Syncrest Inc. Organic zinc compound and production method for organic zinc compound
WO2023234187A1 (ja) * 2022-05-31 2023-12-07 シンクレスト株式会社 有機銅化合物の製造方法
EP4695233A2 (en) * 2023-04-14 2026-02-18 Revolution Medicines, Inc. Synthesis of ras inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
DK0624569T3 (da) * 1991-02-28 1998-10-26 Merrell Pharma Inc MMDA-antagonister
GB9618349D0 (en) 1996-09-03 1996-10-16 Pharmacia Spa N-substituted 2-amino-4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibitory activity
ATE249421T1 (de) * 1997-06-23 2003-09-15 Tanabe Seiyaku Co Inhibitoren der alpha4-beta1 vermittelten zelladhäsion
CN1309702C (zh) * 2005-10-28 2007-04-11 中国科学院上海有机化学研究所 犬尿氨酸酶的特异性抑制剂l-邻甲氧基苯甲酰基丙氨酸的合成方法
CA3216579A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
JP2016513718A (ja) 2013-03-14 2016-05-16 ヴィスタゲン セラピューティクス、インコーポレイテッド キラルキヌレニン化合物及び中間体の合成
CN107417558A (zh) 2013-03-14 2017-12-01 维斯塔津治疗公司 用于合成手性犬尿氨酸化合物的方法
US9666192B2 (en) 2015-05-26 2017-05-30 Nuance Communications, Inc. Methods and apparatus for reducing latency in speech recognition applications
WO2017044516A1 (en) 2015-09-08 2017-03-16 Cephalon, Inc. Prodrugs of chlorokynurenines
CN108139498B (zh) 2015-10-15 2019-12-03 埃克森美孚上游研究公司 具有振幅保持的fwi模型域角度叠加
WO2017065899A1 (en) * 2015-10-16 2017-04-20 Auspex Pharmaceuticals, Inc. Deuterated chlorokynurenines for the treatment of neuropsychiatric disorders
CN107129444B (zh) * 2016-02-29 2018-08-31 尚科生物医药(上海)有限公司 (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法
CN112236412B (zh) * 2018-02-09 2024-01-30 维斯塔津治疗公司 4-氯代犬尿氨酸及中间体的合成

Similar Documents

Publication Publication Date Title
JP5779592B2 (ja) ラコサミドの合成のための方法
JP4770174B2 (ja) グルタミン酸誘導体及びピログルタミン酸誘導体の製造方法並びに新規製造中間体
WO2005033064A1 (en) Process of preparing o-carbamoyl compounds in the presence of active amine group
CN108148044B (zh) 酰胺类化合物及该化合物制备富马酸沃诺拉赞的方法
JP2020519680A (ja) 4−メトキシピロール誘導体の中間体の製造方法
JP2016528271A (ja) □新規な中間体を経由するビフェニルアラニノールの合成
WO2024092892A1 (zh) 依度沙班中间体及其制备方法
US11427530B2 (en) Synthesis of 4-chlorokynurenines and intermediates
WO2019049824A1 (ja) 保護l-カルノシン誘導体、l-カルノシン、および結晶性l-カルノシン亜鉛錯体の製造方法
JP7278775B2 (ja) 長鎖化合物の製造方法
CN107810189B (zh) 用于制备氮芥衍生物的方法
JP4149668B2 (ja) β−ハロゲノ−α−アミノカルボン酸並びにフェニルシステイン誘導体及びその中間体の製造方法
US9790170B2 (en) Method for preparing lacosamide
WO2014141294A2 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
US8853453B2 (en) Processes for reducing impurities in lacosamide
CN112272665A (zh) 制备立他司特的方法
US11414411B2 (en) Chemical process for manufacturing monobactam antibiotic and intermediates thereof
JP4190879B2 (ja) テアニンを製造するための新規な中間体
CN103702981B (zh) 光学活性2-甲基脯氨酸衍生物的制造方法
WO2023033016A1 (ja) アルギニン誘導体
JP2011057619A (ja) 光学活性アミン化合物の製造方法、並びに、ジアステレオマー塩及びその製造方法
KR100880623B1 (ko) 발사르탄의 제조방법
CN114845991A (zh) 合成美法仑的方法
US20060264671A1 (en) Process for the preparation of midodrine, pharmaceutically acceptable salts thereof and intermediates
JP2019059688A (ja) 結晶性l−カルノシン亜鉛錯体の製造方法